Taro Pharmaceutical Industries Ltd(NYSE:TARO) 
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingre...
Website: http://www.taro.com
Founded: 1959
Full Time Employees: 1,464
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2023-03-31 | 2022-03-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-06-30 | 2019-05-22 | 2019-03-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-05-22 | 2017-03-31 | 2016-11-09 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-05-23 | 2013-03-31 | 2012-09-30 | 2012-03-31 | 2011-12-31 | 2011-09-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2009-12-31 | 2009-09-30 | 2009-06-30 | 2009-03-31 | 2008-12-31 | 2008-09-30 | 2007-12-31 | 2006-12-31 | 2005-12-31 | 2004-12-31 | 2003-12-31 |
|---|
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2023-03-31 | 2022-09-30 | 2022-03-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2009-12-31 | 2009-09-30 | 2009-06-30 | 2009-03-31 | 2008-12-31 | 2008-09-30 | 2005-12-31 | 2004-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current assets: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 154,495,000 | 175,191,000 | 251,134,000 | 523,668,000 | 614,888,000 | 605,177,000 | 552,918,000 | 498,796,000 | 532,044,000 | 513,354,000 | 509,361,000 | 560,667,000 | 632,986,000 | 567,451,000 | 566,469,000 | 825,600 | 641,989,000 | 576,611,000 | 569,193,000 | 503,321,000 | 430,713,000 | 600,399,000 | 549,646,000 | 365,638,000 | 438,732,000 | 576,757,000 | 523,214,000 | 487,695,000 | 438,998,000 | 481,641,000 | 283,219,000 | 258,615,000 | 317,873,000 | 209,967,000 | 207,455,000 | 350,611,000 | 273,558,000 | 237,284,000 | 276,995,000 | 288,135,000 | 191,247,000 | 238,266,000 | 150,001,000 | 161,510,000 | 107,703,000 | 78,872,000 | 54,157,000 | 89,477,000 | 86,309,000 | 98,439,000 | 81,704,000 | 72,862,000 | 80,755,000 | 68,828,000 | 66,253,000 | 72,828,000 | 98,630,000 |
short-term and current maturities of long-term bank deposits | 119,980,000 | 35,573,000 | 174,158,000 | 296,188,000 | 419,324,000 | 556,121,000 | 806,558,000 | 782,813,000 | 555,127,000 | 540,326,000 | 532,624,000 | 648,297,000 | |||||||||||||||||||||||||||||||||||||||||||||
marketable securities | 575,814,000 | 568,671,000 | 522,028,000 | 413,322,000 | 410,590,000 | 418,480,000 | 521,041,000 | 543,204,000 | 590,286,000 | 595,383,000 | 542,032,000 | 496,948,000 | 506,751,000 | 481,883,000 | 488,582,000 | 596,744 | 597,533,000 | 549,821,000 | 403,261,000 | 339,444,000 | 207,712,000 | 3,548,000 | 3,422,000 | 3,512,000 | 3,521,000 | 3,572,000 | 3,502,000 | 3,482,000 | 3,425,000 | 3,458,000 | 3,417,000 | 3,364,000 | 3,305,000 | 3,255,000 | 3,102,000 | 3,127,000 | 2,818,000 | 3,183,000 | 3,172,000 | 3,110,000 | 3,043,000 | 7,835,000 | 2,901,000 | 2,889,000 | 2,786,000 | 3,684,000 | 3,693,000 | 5,156,000 | 2,695,000 | ||||||||
accounts receivable and other: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade | 202,260,000 | 248,495,000 | 246,972,000 | 196,671,000 | 216,833,000 | 213,539,000 | 228,825,000 | 231,670,000 | 189,301,000 | 235,221,000 | 227,327,000 | 247,500,000 | 213,514,000 | 237,945,000 | 223,791,000 | 224,007 | 209,135,000 | 206,455,000 | 197,799,000 | 201,710,000 | 185,881,000 | 203,924,000 | 251,623,000 | 249,750,000 | 289,803,000 | 238,611,000 | 279,538,000 | 247,278,000 | 196,795,000 | 222,427,000 | 225,653,000 | 178,732,000 | 103,526,000 | 138,772,000 | 127,010,000 | 127,318,000 | 116,599,000 | 119,810,000 | 134,590,000 | 130,285,000 | 120,832,000 | 102,660,000 | 83,135,000 | 81,815,000 | 76,031,000 | 78,018,000 | 76,671,000 | 72,695,000 | 62,098,000 | 52,954,000 | 124,674,000 | ||||||
other receivables and prepaid expenses | 57,210,000 | 53,097,000 | 59,727,000 | 59,785,000 | 55,596,000 | 53,347,000 | 49,963,000 | 44,947,000 | 45,082,000 | 35,567,000 | 21,115,000 | 26,312,000 | 22,645,000 | 21,393,000 | 23,600,000 | 30,918 | 25,184,000 | 122,965,000 | 168,160,000 | 176,298,000 | 157,755,000 | 266,280,000 | 275,103,000 | 269,150,000 | 271,443,000 | 270,724,000 | 275,025,000 | 271,900,000 | 257,228,000 | 250,911,000 | 262,782,000 | 227,659,000 | 206,265,000 | 162,392,000 | 158,002,000 | 146,040,000 | 133,760,000 | 119,768,000 | 109,711,000 | 111,335,000 | 101,775,000 | 98,501,000 | 94,344,000 | 83,207,000 | 68,865,000 | 52,763,000 | 16,621,000 | ||||||||||
inventories | 226,669,000 | 215,524,000 | 210,439,000 | 182,928,000 | 182,860,000 | 180,292,000 | 169,527,000 | 167,213,000 | 166,223,000 | 153,073,000 | 157,875,000 | 148,439,000 | 148,283,000 | 148,079,000 | 148,047,000 | 153,107 | 141,034,000 | 144,595,000 | 149,186,000 | 150,191,000 | 144,354,000 | 141,045,000 | 145,955,000 | 149,603,000 | 147,945,000 | 138,553,000 | 126,875,000 | 125,856,000 | 119,382,000 | 120,272,000 | 125,077,000 | 125,778,000 | 127,441,000 | 117,639,000 | 119,822,000 | 112,042,000 | 112,537,000 | 109,626,000 | 110,732,000 | 109,891,000 | 104,049,000 | 109,638,000 | 107,378,000 | 92,883,000 | 90,910,000 | 86,024,000 | 78,120,000 | 75,588,000 | 75,273,000 | 65,341,000 | 66,922,000 | 65,522,000 | 66,647,000 | 66,099,000 | 70,999,000 | 76,192,000 | |
total current assets | 1,336,428,000 | 1,356,608,000 | 1,337,886,000 | 1,411,947,000 | 1,480,767,000 | 1,470,835,000 | 1,522,274,000 | 1,485,830,000 | 1,522,936,000 | 1,532,598,000 | 1,457,710,000 | 1,479,866,000 | 1,533,655,000 | 1,482,720,000 | 1,461,748,000 | 1,865,004 | 1,833,199,000 | 1,896,635,000 | 1,906,923,000 | 1,927,085,000 | 1,934,056,000 | 1,999,024,000 | 1,781,875,000 | 1,579,041,000 | 1,685,126,000 | 1,877,595,000 | 1,865,170,000 | 1,708,424,000 | 1,570,950,000 | 1,513,807,000 | 1,351,573,000 | 1,214,763,000 | 1,094,712,000 | 1,051,271,000 | 978,365,000 | 1,096,366,000 | 975,574,000 | 909,771,000 | 841,672,000 | 770,824,000 | 678,716,000 | 653,661,000 | 581,431,000 | 488,231,000 | 395,511,000 | 344,725,000 | 288,557,000 | 314,559,000 | 294,330,000 | 272,378,000 | 280,956,000 | 244,357,000 | 232,620,000 | 226,630,000 | 244,558,000 | 221,698,000 | 333,114,000 |
long-term marketable securities | 404,896,000 | 435,189,000 | 459,639,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment | 190,139,000 | 191,489,000 | 199,692,000 | 196,632,000 | 202,031,000 | 205,508,000 | 206,296,000 | 207,923,000 | 209,228,000 | 209,961,000 | 206,692,000 | 206,727,000 | 205,654,000 | 206,242,000 | 197,896,000 | 198,097 | 194,797,000 | 193,727,000 | 190,468,000 | 187,937,000 | 183,415,000 | 180,085,000 | 173,446,000 | 171,427,000 | 164,598,000 | 159,459,000 | 153,343,000 | 151,053,000 | 152,902,000 | 153,045,000 | 153,488,000 | 154,199,000 | 154,939,000 | 151,416,000 | 150,960,000 | 145,527,000 | 144,073,000 | 145,265,000 | 145,762,000 | 146,812,000 | 147,779,000 | 150,750,000 | 152,532,000 | 154,565,000 | 159,424,000 | 161,671,000 | 163,183,000 | 171,210,000 | 172,212,000 | 180,440,000 | 185,159,000 | 182,406,000 | 183,111,000 | 186,543,000 | 196,466,000 | 269,419,000 | |
deferred income taxes | 103,672,000 | 124,167,000 | 124,882,000 | 125,449,000 | 130,832,000 | 142,007,000 | 134,799,000 | 143,297,000 | 105,389,000 | 106,693,000 | 114,193,000 | 111,809,000 | 108,852,000 | 110,974,000 | 118,915,000 | 126,755 | 122,408,000 | 87,257,000 | 79,643,000 | 125,597,000 | 137,706,000 | 5,489,000 | 12,302,000 | 3,373,000 | 1,096,000 | 462,000 | 31,387,000 | ||||||||||||||||||||||||||||||
goodwill | 17,231,000 | 12,718,000 | 11,820,000 | 7,277,000 | 7,277,000 | 7,265,000 | 7,217,000 | 7,232,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
other assets | 83,147,000 | 64,711,000 | 66,893,000 | 30,191,000 | 30,797,000 | 31,314,000 | 32,207,000 | 32,258,000 | 31,743,000 | 32,361,000 | 33,318,000 | 33,526,000 | 32,495,000 | 31,068,000 | 30,533,000 | 29,940 | 29,340,000 | 29,952,000 | 30,629,000 | 31,311,000 | 31,094,000 | 39,959,000 | 33,173,000 | 33,873,000 | 34,923,000 | 35,806,000 | 20,604,000 | 20,718,000 | 23,746,000 | 24,563,000 | 25,981,000 | 26,873,000 | 27,914,000 | 28,795,000 | 29,942,000 | 26,600,000 | 27,477,000 | 29,945,000 | 30,013,000 | 31,018,000 | 32,041,000 | 45,239,000 | 50,185,000 | 60,211,000 | 71,988,000 | 33,485,000 | 31,203,000 | 28,853,000 | 29,697,000 | 31,430,000 | |||||||
total assets | 2,135,513,000 | 2,107,279,000 | 2,176,362,000 | 2,317,158,000 | 2,413,305,000 | 2,406,873,000 | 2,371,824,000 | 2,346,108,000 | 2,379,693,000 | 2,341,252,000 | 2,290,963,000 | 2,249,706,000 | 2,172,200,000 | 2,135,326,000 | 2,069,518,000 | 2,555,506 | 2,477,889,000 | 2,433,210,000 | 2,421,889,000 | 2,413,817,000 | 2,357,647,000 | 2,289,753,000 | 2,247,179,000 | 2,150,779,000 | 2,168,323,000 | 2,188,033,000 | 2,070,473,000 | 1,901,491,000 | 1,789,017,000 | 1,737,745,000 | 1,599,018,000 | 1,447,923,000 | 1,346,772,000 | 1,284,376,000 | 1,205,024,000 | 1,291,911,000 | 1,170,375,000 | 1,106,636,000 | 1,045,308,000 | 966,382,000 | 876,185,000 | 856,424,000 | 795,845,000 | 713,916,000 | 636,816,000 | 597,581,000 | 553,901,000 | 545,207,000 | 520,254,000 | 508,300,000 | 524,721,000 | 477,941,000 | 467,120,000 | 473,098,000 | 507,198,000 | 579,011,000 | 696,847,000 |
liabilities and shareholders’ equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade payables | 68,484,000 | 61,356,000 | 68,232,000 | 55,228,000 | 62,066,000 | 61,166,000 | 45,409,000 | 39,967,000 | 36,302,000 | 28,858,000 | 37,035,000 | 38,409,000 | 37,210,000 | 35,060,000 | 32,500,000 | 30,207 | 26,513,000 | 25,697,000 | 23,885,000 | 19,387,000 | 23,321,000 | 29,768,000 | 20,527,000 | ||||||||||||||||||||||||||||||||||
settlement and loss contingencies | 140,553,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
returns reserve | 55,865,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accrued income taxes | 33,011,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accrued expenses | 23,953,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
employees and payroll accruals | 23,055,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
medicaid and indirect rebates | 22,403,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other current liabilities | 18,224,000 | 313,495,000 | 363,886,000 | 558,730,000 | 667,084,000 | 615,135,000 | 538,668,000 | 547,349,000 | 560,185,000 | 193,873,000 | 177,144,000 | 171,092,000 | 152,023,000 | 181,761,000 | 186,139,000 | 172,852 | 166,116,000 | 190,059,000 | 189,688,000 | 161,814,000 | 149,989,000 | 71,840,000 | 42,481,000 | ||||||||||||||||||||||||||||||||||
total current liabilities | 385,548,000 | 374,851,000 | 432,118,000 | 613,958,000 | 729,150,000 | 676,301,000 | 584,077,000 | 587,316,000 | 596,487,000 | 222,731,000 | 214,179,000 | 209,501,000 | 189,233,000 | 216,821,000 | 218,639,000 | 203,059 | 192,629,000 | 215,756,000 | 213,573,000 | 201,546,000 | 205,767,000 | 209,837,000 | 239,463,000 | 225,972,000 | 243,378,000 | 245,462,000 | 290,418,000 | 275,970,000 | 249,004,000 | 310,005,000 | 266,521,000 | 234,684,000 | 250,495,000 | 253,304,000 | 243,933,000 | 227,390,000 | 211,463,000 | 192,531,000 | 173,842,000 | 172,189,000 | 158,111,000 | 198,899,000 | 190,383,000 | 173,006,000 | 132,362,000 | 134,444,000 | 132,934,000 | 195,107,000 | 214,972,000 | 220,808,000 | 225,503,000 | 193,059,000 | 185,178,000 | 206,312,000 | 170,285,000 | 131,529,000 | |
long-term liabilities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other long-term liabilities | 19,106,000 | 32,799,000 | 5,367,000 | 3,996,000 | 4,934,000 | 5,512,000 | 4,931,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
total long-term liabilities | 19,106,000 | 32,799,000 | 8,762,000 | 23,144,000 | 34,399,000 | 171,861,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
commitments and contingent liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities | 404,654,000 | 400,999,000 | 464,917,000 | 644,050,000 | 755,249,000 | 711,416,000 | 621,251,000 | 627,363,000 | 705,555,000 | 231,493,000 | 222,359,000 | 218,400,000 | 197,355,000 | 224,204,000 | 223,999,000 | 207,717 | 197,825,000 | 222,811,000 | 218,415,000 | 206,316,000 | 211,762,000 | 215,947,000 | 244,920,000 | 231,152,000 | 248,895,000 | 250,889,000 | 295,013,000 | 285,619,000 | 259,004,000 | 320,362,000 | 276,587,000 | 244,987,000 | 260,827,000 | 263,783,000 | 255,160,000 | 249,901,000 | 243,300,000 | 215,675,000 | 197,202,000 | 205,199,000 | 191,298,000 | 233,466,000 | 224,782,000 | 210,956,000 | 177,269,000 | 177,019,000 | 175,242,000 | 247,699,000 | 264,158,000 | 270,473,000 | 296,033,000 | 266,869,000 | 268,528,000 | 301,156,000 | 342,146,000 | ||
shareholders’ equity: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
taro shareholders' equity: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ordinary shares of nis 0.0001 par value: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
authorized at march 31, 2023 and march 31, 2022: 200,000,000 shares; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued at march 31, 2023 and march 31, 2022: 45,116,262 shares | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
outstanding at march 31, 2023 and march 31, 2022: 37,584,631 shares | 679,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
founders’ shares of nis 0.00001 par value: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
authorized, issued and outstanding at march 31, 2023 and march 31, 2022: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2,600 shares | 1,000 | 1,000 | 1,000 | 1,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
additional paid-in capital | 262,445,000 | 262,445,000 | 262,445,000 | 261,008,000 | 253,577,000 | 163,769,000 | 184,562,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
accumulated other comprehensive loss, net of taxes | -174,996,000 | -168,965,000 | -163,037,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
treasury stock | -721,494,000 | -1,329,000 | -1,329,000 | -1,387,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
7,531,631 shares | -771,406,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accumulated earnings | 2,414,136,000 | 2,388,691,000 | 2,725,270,000 | 609,245,000 | 295,787,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
total shareholders’ equity | 1,730,859,000 | 1,711,445,000 | 2,109,759,000 | 890,961,000 | 571,063,000 | 236,865,000 | 368,120,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and shareholders’ equity | 2,135,513,000 | 2,107,279,000 | 2,176,362,000 | 2,341,252,000 | 1,737,745,000 | 1,599,018,000 | 1,447,923,000 | 1,346,772,000 | 1,284,376,000 | 1,205,024,000 | 1,291,911,000 | 1,170,375,000 | 1,106,636,000 | 1,045,308,000 | 966,382,000 | 876,185,000 | 856,424,000 | 795,845,000 | 713,916,000 | 636,816,000 | 597,581,000 | 553,901,000 | 545,207,000 | 508,300,000 | 579,011,000 | 696,847,000 | |||||||||||||||||||||||||||||||
short-term bank deposits | 95,630,000 | 47,586,000 | 655,982,000 | 571,147,000 | 555,122,000 | 434,899,000 | 451,157,000 | 420,333,000 | 335,999,000 | 418,946,000 | 362,901,000 | 357,157,000 | 328,803,000 | 312,603,000 | 198,973,000 | 120,570,000 | 151,317,000 | 72,440,000 | 89,814,000 | 44,641,000 | 41,642,000 | 41,105,000 | 31,000,000 | 37,250,000 | 26,295,000 | 9,427,000 | 23,063,000 | 10,000,000 | |||||||||||||||||||||||||||||
deferred taxes and other long-term liabilities | 26,148,000 | 30,092,000 | 26,099,000 | 35,115,000 | 37,174,000 | 40,047,000 | 109,068,000 | 8,180,000 | 8,899,000 | 8,122,000 | 7,383,000 | 5,360,000 | 4,658 | 5,196,000 | 7,055,000 | 4,842,000 | 4,770,000 | 5,995,000 | 6,110,000 | 5,457,000 | 5,180,000 | 5,517,000 | 5,427,000 | 4,595,000 | 5,150,000 | 5,381,000 | 4,857,000 | 4,864,000 | 4,591,000 | 5,120,000 | 5,139,000 | 6,116,000 | 6,049,000 | 6,240,000 | 6,618,000 | 7,258,000 | 11,839,000 | 10,491,000 | 11,100,000 | ||||||||||||||||||
taro shareholders’ equity | 1,706,280,000 | 1,411,719,000 | 1,316,794,000 | 1,197,431,000 | 1,080,759,000 | 1,015,507,000 | 944,697,000 | 1,036,943,000 | 931,311,000 | 886,347,000 | 843,391,000 | 756,842,000 | 680,678,000 | 619,008,000 | 567,264,000 | 499,109,000 | |||||||||||||||||||||||||||||||||||||||||
authorized at march 31, 2022 and march 31, 2021: 200,000,000 shares; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued at march 31, 2022 and march 31, 2021: 45,116,262 shares | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
outstanding at march 31, 2022 and march 31, 2021: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
37,584,631 and 37,926,044 shares, respectively | 679,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
authorized, issued and outstanding at march 31, 2022 and march 31, 2021: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
7,531,631 and 7,190,218 shares, respectively | -771,406,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
taro shareholders' equity | 1,711,445,000 | 1,673,108,000 | 1,658,056,000 | 1,703,649,000 | 1,759,668,000 | 1,727,957,000 | 1,683,279,000 | 2,103,864,000 | 2,062,934,000 | 2,025,630,000 | 1,969,201,000 | 1,905,536,000 | 1,839,976,000 | 2,342,409 | 2,274,672,000 | 2,205,158,000 | 2,198,374,000 | 2,201,042,000 | 2,139,515,000 | 2,067,494,000 | 1,995,923,000 | 1,913,385,000 | 1,913,429,000 | 1,931,142,000 | 1,769,522,000 | 1,610,032,000 | 1,524,312,000 | 455,411,000 | 417,066,000 | ||||||||||||||||||||||||||||
non-controlling interest | -8,192,000 | -9,095,000 | -9,212,000 | -9,141,000 | 5,895,000 | 5,670,000 | 5,676,000 | 5,644,000 | 5,586,000 | 5,543,000 | 5,380 | 5,392,000 | 5,241,000 | 5,100,000 | 6,459,000 | 6,370,000 | 6,312,000 | 6,336,000 | 6,242,000 | 5,999,000 | 6,002,000 | 5,938,000 | 5,840,000 | 5,701,000 | 5,664,000 | 5,637,000 | 5,505,000 | 5,186,000 | 5,086,000 | 5,167,000 | 5,067,000 | 4,764,000 | 4,614,000 | 4,715,000 | 4,341,000 | 4,209,000 | 3,950,000 | 3,799,000 | 3,851,000 | 4,136,000 | 3,496,000 | ||||||||||||||||
liabilities and shareholders' equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and shareholders' equity | 2,317,158,000 | 2,413,305,000 | 2,406,873,000 | 2,371,824,000 | 2,346,108,000 | 2,379,693,000 | 2,290,963,000 | 2,249,706,000 | 2,172,200,000 | 2,135,326,000 | 2,069,518,000 | 2,555,506 | 2,477,889,000 | 2,433,210,000 | 2,421,889,000 | 2,413,817,000 | 2,357,647,000 | 2,289,753,000 | 2,247,179,000 | 2,150,779,000 | 2,168,323,000 | 2,188,033,000 | 2,070,473,000 | 1,901,491,000 | 1,789,017,000 | 524,721,000 | 477,941,000 | 467,120,000 | 507,198,000 | ||||||||||||||||||||||||||||
authorized at march 31, 2020 and march 31, 2019: 200,000,000 shares; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued at march 31, 2020 and march 31, 2019: 45,116,262 shares | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
outstanding at march 31, 2020 and march 31, 2019: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
38,258,077 and 38,538,796 shares, respectively | 679,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
authorized, issued and outstanding at march 31, 2020 and march 31, 2019: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
long-term deposits and marketable securities | 417,778,000 | 291,544,000 | 304,322,000 | 260,426,000 | 335,710 | 298,145,000 | 225,639,000 | 214,226,000 | 141,887,000 | 71,376,000 | |||||||||||||||||||||||||||||||||||||||||||||||
corporate tax receivable | 9,476,000 | 25,969,000 | 11,259,000 | 34,628 | 44,166,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
long-term assets held for sale | 1,083,000 | 1,015,000 | 999,000 | 1,062,000 | 1,058,000 | 1,081,000 | 1,034,000 | 1,066,000 | 64,000 | 67,000 | 72,000 | 73,000 | 73,000 | 71,000 | 69,000 | 67,000 | 69,000 | 68,000 | 66,000 | 81,000 | 441,000 | 470,000 | |||||||||||||||||||||||||||||||||||
trade payables and other current liabilities | 201,546,000 | 205,767,000 | 209,837,000 | 239,463,000 | 225,972,000 | 243,378,000 | 245,462,000 | 290,418,000 | 275,030,000 | 309,093,000 | 265,623,000 | 223,206,000 | 238,302,000 | 241,330,000 | 231,849,000 | 215,510,000 | 199,966,000 | 162,756,000 | 161,504,000 | 147,545,000 | 187,942,000 | 147,160,000 | 104,998,000 | 103,535,000 | 104,739,000 | ||||||||||||||||||||||||||||||||
long-term bank deposits | 70,685,000 | 258,685,000 | 366,438,000 | 283,676,000 | 115,173,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
restricted short-term bank deposits | 199,000 | 204,000 | 215,000 | 231,000 | 227,000 | 7,430,000 | 7,430,000 | 7,430,000 | 7,430,000 | 6,980,000 | 15,780,000 | 16,080,000 | 5,250,000 | 5,250,000 | 5,250,000 | 6,250,000 | 6,250,000 | 6,250,000 | 6,859,000 | ||||||||||||||||||||||||||||||||||||||
current maturities of long-term debt | 940,000 | 925,000 | 912,000 | 898,000 | 11,478,000 | 12,193,000 | 11,974,000 | 12,084,000 | 11,880,000 | 11,497,000 | 11,330,000 | 11,086,000 | 10,685,000 | 10,566,000 | 10,957,000 | 17,073,000 | 13,167,000 | 13,947,000 | 13,597,000 | 13,310,000 | 16,838,000 | 17,005,000 | 14,728,000 | ||||||||||||||||||||||||||||||||||
long-term debt | 4,499,000 | 4,976,000 | 5,209,000 | 5,439,000 | 5,665,000 | 5,888,000 | 6,107,000 | 17,372,000 | 17,214,000 | 17,269,000 | 17,244,000 | 26,961,000 | 26,947,000 | 27,949,000 | 27,614,000 | 30,692,000 | 33,068,000 | 32,084,000 | 31,208,000 | 38,372,000 | 161,949,000 | 187,346,000 | |||||||||||||||||||||||||||||||||||
long-term receivables and other assets | 31,356,000 | 21,296,000 | 46,330,000 | 67,976,000 | 52,088,000 | 69,207,000 | 52,894,000 | 45,757,000 | 23,418,000 | 23,251,000 | 23,227,000 | 27,929,000 | 18,733,000 | 18,672,000 | 19,972,000 | 23,131,000 | 25,881,000 | 31,696,000 | 30,974,000 | 27,856,000 | 19,527,000 | ||||||||||||||||||||||||||||||||||||
long-term receivables | 41,419,000 | 19,984,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade payable and other current liabilities | 248,079,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
long -term debt, net of current maturities | 4,740,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred income taxes and other long-term liabilities | 5,260,000 | 4,667,000 | 5,623,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
intangible assets and deferred costs | 15,607,000 | 19,172,000 | 23,756,000 | 60,673,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
taro shareholders’ equity: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
authorized at march 31, 2013 and march 31, 2012: 200,000,000 shares; issued at march 31, 2013 and march 31, 2012: 45,091,562 and 44,800,007 shares, respectively outstanding at march 31, 2013 and march 31, 2012: 44,768,087 and 44,476,532 shares, respectively | 679,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
authorized, issued and outstanding at march 31, 2013 and march 31, 2012: 2,600 shares | 1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accumulated other comprehensive income, net of taxes | 16,743,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable and other: trade | 120,239,000 | 111,130,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
assets held for sale | 71,000 | 462,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
short-term bank credit and short-term loans | 12,679,000 | 13,417,000 | 17,312,000 | 14,885,000 | 92,549,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
authorized at december 31, 2011 and 2010: 200,000,000 shares; issued at december 31, 2011 and 2010: 44,799,507 and 43,341,732 shares, respectively | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
outstanding at december 31, 2011 and 2010: 44,476,032 and 43,018,257 shares, respectively | 679,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
authorized, issued and outstanding at december 31, 2011 and 2010: 2,600 shares | 1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accumulated other comprehensive income | 18,549,000 | 11,811,000 | 13,477,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
other receivables, prepaid expenses and other | 45,556,000 | 23,820,000 | 21,837,000 | 21,226,000 | 19,605,000 | 12,865,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
long-term investments | 30,173,000 | 25,953,000 | 22,509,000 | 23,307,000 | 29,753,000 | 21,481,000 | 19,959,000 | 20,713,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
shareholders' equity | 378,659,000 | 297,508,000 | 256,096,000 | 237,827,000 | 228,688,000 | 211,072,000 | 198,592,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
short-term bank credits | 74,851,000 | 88,771,000 | 89,935,000 | 96,792,000 | 87,285,000 | 90,292,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable and accrued expenses | 103,418,000 | 109,196,000 | 99,192,000 | 77,868,000 | 66,207,000 | 80,898,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
long-term liabilities | 40,113,000 | 37,591,000 | 49,050,000 | 54,767,000 | 64,700,000 | 86,479,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
deferred taxes and other liabilities | 12,479,000 | 11,595,000 | 21,480,000 | 19,043,000 | 18,650,000 | 8,365,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
shareholders’ equity | 520,254,000 | 206,042,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangible assets and deferred charges | 21,537,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current maturities of long-term liabilities | 29,265,000 | 29,519,000 | 27,906,000 | 28,679,000 | 32,166,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable - trade | 79,252,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable - other and prepaid expenses | 23,765,000 | 17,133,000 | 14,789,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable – trade | 82,590,000 | 64,179,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
taro pharmaceutical industries ltd. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
consolidated balance sheets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
u.s. dollars and shares in thousands | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable, net – trade | 72,037,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable – other and prepaid expenses | 35,269,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred taxes and other assets | 45,461,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
short-term bank liabilities* | 93,248,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
share capital: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
authorized at december 31, 2005: 200,000,000 shares; issued | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
at december 31, 2005: 29,566,749 shares, | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
outstanding at december 31, 2005: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
29,300,865 shares | 679,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
authorized, issued and outstanding at december 31, 2005: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
retained earnings | 61,992,000 | 170,749,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangible assets and deferred | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charges | 63,174,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other and accrued expenses | 31,779,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accrued severance pay and other long term liabilities | 2,442,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
minority interest | 694,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total long-term liabilities and minority | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest | 197,198,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred stock-based compensation |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2012-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities: | |||||||||||||||||||||
net income | 23,316,000 | -18,767,000 | -28,882,000 | 33,036,000 | 45,062,000 | -449,956,000 | 54,421,000 | 67,678,000 | 56,210,000 | 66,241,000 | 62,548,000 | 67,428,000 | -13,567,000 | 16,614,000 | 52,482,000 | 54,555,000 | 82,962,000 | 139,911,000 | 123,900,000 | 109,893,000 | 47,403,000 |
adjustments required to reconcile net income to net cash from operating activities: | |||||||||||||||||||||
depreciation and amortization | 6,449,000 | 6,346,000 | 6,343,000 | 5,976,000 | 5,790,000 | 5,571,000 | 5,282,000 | 5,447,000 | 5,583,000 | 5,071,000 | 4,516,000 | 4,299,000 | 2,758,000 | 4,228,000 | 4,019,000 | 3,775,000 | 3,762,000 | 3,670,000 | 3,705,000 | 3,692,000 | 4,598,000 |
realized loss on sale of long-lived assets | |||||||||||||||||||||
change in derivative instruments | -148,000 | -166,000 | 154,000 | 552,000 | -19,000 | -923,000 | 746,000 | -637,000 | -337,000 | -2,421,000 | -1,020,000 | 3,546,000 | -6,774,000 | -253,000 | -1,295,000 | -3,093,000 | -3,067,000 | 2,164,000 | -334,000 | 2,671,000 | -3,392,000 |
effect of exchange differences on intercompany balances | |||||||||||||||||||||
foreign exchange effect of marketable securities and bank deposits | |||||||||||||||||||||
adjustments to opening balance sheet | |||||||||||||||||||||
deferred income taxes | 5,683,000 | 11,244,000 | -6,536,000 | 7,714,000 | -37,224,000 | -2,367,000 | 9,660,000 | -2,378,000 | -2,628,000 | 2,930,000 | -3,280,000 | 1,575,000 | 55,266,000 | 45,727,000 | 10,988,000 | 4,825,000 | 86,844,000 | -1,716,000 | 8,860,000 | -20,282,000 | 4,075,000 |
decrease (increase) in trade receivables | -7,894,000 | 24,431,000 | 3,838,000 | -15,404,000 | 18,270,000 | 9,879,000 | |||||||||||||||
increase in other receivables, prepaid expenses and other | -535,000 | ||||||||||||||||||||
increase in inventories | -68,000 | -2,568,000 | -10,765,000 | -2,314,000 | -990,000 | -13,150,000 | 4,802,000 | -9,436,000 | -155,000 | -205,000 | 4,817,000 | 725,000 | -3,872,000 | -2,114,000 | 5,350,000 | 2,491,000 | -2,421,000 | -9,190,000 | -1,583,000 | ||
decrease (increase) in income tax receivables | |||||||||||||||||||||
increase in trade payables | -521,000 | ||||||||||||||||||||
increase in other accounts payable and accrued expenses | 3,241,000 | ||||||||||||||||||||
increase in income tax payables | 12,138,000 | ||||||||||||||||||||
expense from amortization of marketable securities bonds | 3,108,000 | 2,179,000 | |||||||||||||||||||
net cash from operating activities | -52,016,000 | 43,993,000 | 51,055,000 | 42,862,000 | -112,257,000 | 64,110,000 | 49,597,000 | 98,650,000 | 40,754,000 | 82,604,000 | 75,210,000 | 82,440,000 | 58,560,000 | 87,098,000 | 66,029,000 | 72,668,000 | 117,080,000 | 127,778,000 | 136,712,000 | 55,965,000 | 78,094,000 |
capital expenditures | -523,000 | 1,225,000 | 2,544,000 | -957,000 | 106,000 | 1,304,000 | -2,000 | -521,000 | -317,000 | 2,317,000 | 435,000 | 1,823,000 | 737,000 | 655,000 | -445,000 | 1,180,000 | 338,000 | 0 | 0 | 0 | -977,000 |
free cash flows | -52,539,000 | 45,218,000 | 53,599,000 | 41,905,000 | -112,151,000 | 65,414,000 | 49,595,000 | 98,129,000 | 40,437,000 | 84,921,000 | 75,645,000 | 84,263,000 | 59,297,000 | 87,753,000 | 65,584,000 | 73,848,000 | 117,418,000 | 127,778,000 | 136,712,000 | 55,965,000 | 77,117,000 |
cash flows from investing activities: | |||||||||||||||||||||
purchase of property, plant and equipment | -1,610,000 | ||||||||||||||||||||
investment in other intangible assets | -35,000 | -72,000 | -44,000 | -41,000 | -13,000 | -63,000 | -767,000 | -971,000 | -15,000 | -30,000 | -1,049,000 | -45,000 | 19,000 | 502,000 | -2,056,000 | -11,000 | -11,000 | ||||
investment in short-term bank deposits | |||||||||||||||||||||
investment in marketable securities | -12,500,000 | -40,825,000 | -107,424,000 | -9,070,000 | -51,391,000 | -107,644,000 | -4,909,000 | ||||||||||||||
proceeds from marketable securities | |||||||||||||||||||||
(investment in) proceeds from acquisitions and sale of long-lived assets | |||||||||||||||||||||
cash acquired from acquisition | |||||||||||||||||||||
net cash from investing activities | -31,526,000 | -16,427,000 | 21,946,000 | 13,004,000 | 78,812,000 | -46,021,000 | -44,403,000 | -123,617,000 | -113,073,000 | -17,069,000 | 115,635,000 | 8,263,000 | -540,373,000 | -6,732,000 | 37,225,000 | -234,801,000 | -41,689,000 | 86,539,000 | -100,764,000 | -61,864,000 | 15,586,000 |
cash flows from financing activities: | |||||||||||||||||||||
repurchase of treasury stock | |||||||||||||||||||||
net cash from financing activities | -6,615,000 | -18,319,000 | -20,953,000 | -157,000 | -7,749,000 | -24,655,000 | 465,205,000 | -14,504,000 | -31,928,000 | -8,489,000 | -25,185,000 | -29,094,000 | -108,129,000 | -132,489,000 | -6,588,000 | ||||||
effect of exchange rate changes on cash and cash equivalents | -1,063,000 | 464,000 | 211,000 | 1,499,000 | 197,000 | 601,000 | -1,044,000 | 515,000 | -670,000 | 2,962,000 | 10,000 | 1,282,000 | 936,000 | 547,000 | -1,215,000 | -913,000 | 363,000 | 1,173,000 | |||
increase in cash and cash equivalents | 9,711,000 | 52,259,000 | 18,690,000 | -72,319,000 | 65,535,000 | 183,611,000 | 65,378,000 | 50,753,000 | 88,265,000 | ||||||||||||
cash and cash equivalents at the beginning of the period | 150,001,000 | ||||||||||||||||||||
cash and cash equivalents at the end of the period | 238,266,000 | ||||||||||||||||||||
supplemental disclosure of cash flow transactions: | |||||||||||||||||||||
cash paid during the year for: | |||||||||||||||||||||
income taxes | 1,199,000 | 3,333,000 | 5,208,000 | 3,573,000 | 13,477,000 | 7,119,000 | 15,763,000 | 16,932,000 | 11,409,000 | 10,432,000 | 5,151,000 | 36,830,000 | 3,564,000 | 2,409,000 | 10,588,000 | 29,595,000 | 1,039,000 | ||||
cash received during the year for: | |||||||||||||||||||||
non-cash investing transactions: | |||||||||||||||||||||
purchase of property, plant and equipment included in accounts payable | -523,000 | 1,225,000 | 2,544,000 | -957,000 | 106,000 | 1,304,000 | -2,000 | -521,000 | -317,000 | 2,317,000 | 435,000 | 1,823,000 | 737,000 | 655,000 | -445,000 | 1,180,000 | 338,000 | ||||
adjustment to purchase price | |||||||||||||||||||||
investment in intangible assets on credit | |||||||||||||||||||||
non-cash financing transactions: | |||||||||||||||||||||
purchase of treasury stock | -6,615,000 | -18,319,000 | -20,953,000 | -7,749,000 | -24,655,000 | -34,795,000 | -14,504,000 | -31,928,000 | -8,489,000 | -29,094,000 | -108,129,000 | -132,489,000 | |||||||||
purchase of marketable securities | 8,153,000 | 2,436,000 | -2,539,000 | 8,629,000 | 1,692,000 | ||||||||||||||||
realized losss on sale of long-lived assets | |||||||||||||||||||||
effect of change in exchange rate on marketable securities and bank deposits | 993,000 | -589,000 | |||||||||||||||||||
increase in trade receivables | -3,295,000 | -14,627,000 | -2,897,000 | 16,142,000 | -2,126,000 | 39,935,000 | -51,220,000 | ||||||||||||||
decrease (increase) in other receivables, income tax receivables, prepaid expenses and other | |||||||||||||||||||||
decrease in trade, income tax, accrued expenses and other payables | |||||||||||||||||||||
purchase of plant, property & equipment | -1,976,000 | -3,855,000 | -2,773,000 | -5,257,000 | -3,820,000 | -5,133,000 | -5,747,000 | -5,634,000 | -7,969,000 | -6,057,000 | -6,078,000 | -7,360,000 | -5,933,000 | -7,252,000 | -4,557,000 | -7,139,000 | -10,054,000 | -9,184,000 | |||
proceeds from (investment in) marketable securities | 24,763,000 | 18,302,000 | 15,000 | 0 | 80,000 | ||||||||||||||||
decrease in cash and cash equivalents | 3,993,000 | 65,872,000 | 72,608,000 | -169,686,000 | -73,094,000 | -138,025,000 | |||||||||||||||
cash and cash equivalents at beginning of period | 0 | 605,177,000 | 0 | 0 | 0 | 513,354,000 | 0 | 0 | 567,451,000 | 0 | 576,611,000 | 23,788,000 | 0 | 0 | 600,399,000 | 0 | 0 | 576,757,000 | |||
cash and cash equivalents at end of period | -91,220,000 | 614,888,000 | 52,259,000 | 54,122,000 | -33,248,000 | 532,044,000 | -51,306,000 | -72,319,000 | 632,986,000 | 183,611,000 | 641,989,000 | 10,142,000 | 65,872,000 | 72,608,000 | 430,713,000 | 184,008,000 | -73,094,000 | 438,732,000 | |||
increase in income tax receivables | |||||||||||||||||||||
(investment in) proceeds from acquisitions, net of sale of long-lived assets | |||||||||||||||||||||
decrease in trade receivables | 15,288,000 | 45,921,000 | |||||||||||||||||||
increase in other receivables, income tax receivables, prepaid expenses and other | 126,000 | -2,598,000 | -4,363,000 | -3,511,000 | |||||||||||||||||
increase in trade, income tax, accrued expenses and other payables | -112,193,000 | 52,211,000 | 77,287,000 | -2,289,000 | |||||||||||||||||
(investment in) proceeds from marketable securities | -116,986,000 | -206,464,000 | -275,128,000 | ||||||||||||||||||
realized gain on sale of long-lived assets | -4,000 | ||||||||||||||||||||
purchase (sale) of marketable securities | 3,179,000 | -1,855,000 | |||||||||||||||||||
income from marketable securities | -525,000 | -310,000 | -1,470,000 | 1,655,000 | -909,000 | -521,000 | |||||||||||||||
purchase of intangible assets | -250,000 | ||||||||||||||||||||
effect of change in exchange rate on marketable securities, bank deposits and inter-company balances | |||||||||||||||||||||
loss (income) from marketable securities | 1,572,000 | 760,000 | 247,000 | ||||||||||||||||||
effect of change in exchange rate on inter-company balances, marketable securities and bank deposits | -1,841,000 | -1,728,000 | -4,851,000 | -586,000 | -5,624,000 | 17,147,000 | -28,918,000 | 84,658,000 | |||||||||||||
increase in other receivables, income tax receivable, prepaid expenses and other | -3,462,000 | 8,402,000 | -15,876,000 | -21,483,000 | 19,612,000 | ||||||||||||||||
increase in trade, income tax, accrued expenses, and other payables | 483,957,000 | ||||||||||||||||||||
(sale) purchase of marketable securities | -745,000 | ||||||||||||||||||||
realized loss on sale of long-lived assets and marketable securities | |||||||||||||||||||||
decrease in other receivables, prepaid expenses and other | |||||||||||||||||||||
decrease in income tax receivables | |||||||||||||||||||||
proceeds from short-term bank deposits | 174,158,000 | 51,345,000 | -64,471,000 | 4,044,000 | 174,911,000 | 46,940,000 | |||||||||||||||
proceeds from long-term deposits and other assets | 0 | 70,685,000 | 18,000 | ||||||||||||||||||
proceeds from (investment in) sale of long-lived assets | |||||||||||||||||||||
dividends paid | |||||||||||||||||||||
decrease in other receivables, income tax receivable, prepaid expenses and other | 5,223,000 | 6,513,000 | 15,671,000 | ||||||||||||||||||
(income) income from marketable securities | 28,000 | ||||||||||||||||||||
sale of marketable securities | 19,000 | ||||||||||||||||||||
realized gain on sale of marketable securities | |||||||||||||||||||||
decrease in trade, income tax, accrued expenses, and other payables | 10,826,000 | -22,965,000 | 11,102,000 | -17,408,000 | -9,746,000 | -3,962,000 | -3,377,000 | ||||||||||||||
investment in the sale of plant, property & equipment | |||||||||||||||||||||
realized loss on sale of marketable securities and long-lived assets | |||||||||||||||||||||
proceeds from the sale of long-lived assets | |||||||||||||||||||||
realized gain on sale of marketable securities and long-lived assets | 25,000 | -7,000 | 257,000 | -29,000 | 372,000 | -247,000 | |||||||||||||||
decrease (increase) in other receivables, income tax receivable, prepaid expenses and other | 9,472,000 | 52,479,000 | -73,781,000 | 3,690,000 | |||||||||||||||||
proceeds from the sale of property, plant and equipment | |||||||||||||||||||||
decrease (increase) in inventories | 2,653,000 | ||||||||||||||||||||
impairment of long-lived assets | |||||||||||||||||||||
proceeds from (investment in) long-term deposits and other assets | 112,197,000 | ||||||||||||||||||||
impairment for long-lived assets | 0 | 76,000 | 108,000 | ||||||||||||||||||
effect of change in exchange rate on inter-company balances and bank deposits | -4,661,000 | 39,486,000 | 22,078,000 | -20,983,000 | -13,135,000 | 4,101,000 | |||||||||||||||
(investment in) proceeds from other intangible assets | |||||||||||||||||||||
non-cash operating transactions: | |||||||||||||||||||||
sale of intangible asset | |||||||||||||||||||||
investment in long-term deposits and other assets | -19,824,000 | -138,289,000 | -143,503,000 | ||||||||||||||||||
cash paid during the quarter for: | |||||||||||||||||||||
· | |||||||||||||||||||||
adjustments required to reconcile net income to net cash | |||||||||||||||||||||
provided by operating activities: | |||||||||||||||||||||
accrued severance pay and other long-term liabilities | -210,000 | ||||||||||||||||||||
(gain) loss on sale of long-lived assets | |||||||||||||||||||||
realized (gain) loss on sale of marketable securities | |||||||||||||||||||||
foreign exchange effect of bank deposits | |||||||||||||||||||||
decrease in long-term debt due to currency fluctuations | |||||||||||||||||||||
decrease (increase) in other long-term assets | |||||||||||||||||||||
decrease in trade payables | |||||||||||||||||||||
proceeds from (investment in) other assets | |||||||||||||||||||||
proceeds from (investment in) short-term bank deposits | -54,684,000 | 112,510,000 | 47,590,000 | 90,754,000 | 18,045,000 | ||||||||||||||||
proceeds from restricted bank deposits | 4,014,000 | ||||||||||||||||||||
(investment in) proceeds from long-term deposits and other assets | |||||||||||||||||||||
proceeds from sale of long-lived assets | 28,000 | ||||||||||||||||||||
proceeds from issuance of shares | 7,000 | ||||||||||||||||||||
repayment of long-term debt | |||||||||||||||||||||
interest | 216,000 | ||||||||||||||||||||
non-cash investing and financing transactions: | |||||||||||||||||||||
realized (gain) loss on sale of marketable securities and long-lived assets | -8,512,000 | ||||||||||||||||||||
decrease in trade, income tax and other payables and accrued expenses | 9,189,000 | -17,311,000 | -3,420,000 | ||||||||||||||||||
proceeds from (investment in) other intangible assets | |||||||||||||||||||||
proceeds from other assets | |||||||||||||||||||||
effect of change in exchange rate on inter-company balances | |||||||||||||||||||||
increase in trade, income tax and other payables and accrued expenses | |||||||||||||||||||||
(investment in) proceeds from other intangible assets and long-lived assets | |||||||||||||||||||||
change in deferred charges and other assets | 8,000 | ||||||||||||||||||||
share-based compensation expense | |||||||||||||||||||||
loss on sale of long-lived assets | 22,000 | ||||||||||||||||||||
effect of exchange differences on inter-company balances | 2,104,000 | ||||||||||||||||||||
increase in long-term debt due to currency fluctuations | 814,000 | ||||||||||||||||||||
decrease in long-term receivables, prepaid expenses and other | |||||||||||||||||||||
investment in other assets | |||||||||||||||||||||
excess tax benefits from share-based payment arrangements | |||||||||||||||||||||
purchase of property, plant and equipment on credit | 633,000 | ||||||||||||||||||||
increase in long-term receivables, prepaid expenses and other | |||||||||||||||||||||
(investment in) proceeds from short-term bank deposits | |||||||||||||||||||||
proceeds from (investment in) restricted bank deposits | |||||||||||||||||||||
proceeds from sale of (investment in) marketable securities | |||||||||||||||||||||
repayment of short-term bank debt | |||||||||||||||||||||
proceeds from long-term debt and capital leases | |||||||||||||||||||||
(a) non-cash investing and financing transactions: | |||||||||||||||||||||
decrease in long-term receivables and other assets | 53,000 | ||||||||||||||||||||
proceeds from short-term bank debt | |||||||||||||||||||||
(repayment of) proceeds from long-term debt | -6,595,000 | ||||||||||||||||||||
decrease (increase) in long-term receivables and other assets | |||||||||||||||||||||
(investment in) proceeds from restricted bank deposits | |||||||||||||||||||||
proceeds from sale (purchase) of marketable securities | |||||||||||||||||||||
(repayment of) proceeds from short-term bank debt | |||||||||||||||||||||
cash and cash equivalents at the beginning of the year | |||||||||||||||||||||
cash and cash equivalents at the end of the year | |||||||||||||||||||||
minority interest in earnings (losses) of a subsidiary | |||||||||||||||||||||
compensation in respect of options granted to non-employees | |||||||||||||||||||||
accrued severance pay | |||||||||||||||||||||
capital gain on sale of property, plant and equipment | |||||||||||||||||||||
currency fluctuation of long-term debt | |||||||||||||||||||||
tax benefit from exercise of options | |||||||||||||||||||||
increase in other accounts receivable and prepaid expenses | |||||||||||||||||||||
increase in income taxes payable | |||||||||||||||||||||
net cash provided (used in) by operating activities | |||||||||||||||||||||
acquisition of thames pharmacal company, inc. | |||||||||||||||||||||
purchase of product rights | |||||||||||||||||||||
long-term and other deposits | |||||||||||||||||||||
investment in restricted short-term bank deposits | |||||||||||||||||||||
proceeds from sale of property, plant and equipment | |||||||||||||||||||||
proceeds from exercise of options and issuance of shares of espp | |||||||||||||||||||||
proceeds from long-term debt | |||||||||||||||||||||
short-term bank credit and short-term loans | |||||||||||||||||||||
supplemental disclosure of cash flow transaction: | |||||||||||||||||||||
(a) acquisition of thames pharmacal company, inc.: | |||||||||||||||||||||
estimated fair value of assets acquired and liabilities assumed at the date of acquisition: | |||||||||||||||||||||
working capital deficiency | |||||||||||||||||||||
property, plant and equipment | |||||||||||||||||||||
intangible assets | |||||||||||||||||||||
goodwill | |||||||||||||||||||||
(b) non-cash investing and financing transactions: |